The role of thymosin-β4 in kidney disease

Bibliography

• Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med 2005;11(9):421-9
   PubMed Web of Science ®Google Scholar
• Goldstein AL, Hannappel E, Sosne G, et al. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther 2012;12(1):37-51
   PubMed Web of Science ®Google Scholar
• Bock-Marquette I, Saxena A, White MD, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 2004;432(7016):466-72
   PubMed Web of Science ®Google Scholar
• Lee SJ, So IS, Park SY, et al. Thymosin beta4 is involved in stabilin-2 mediated apoptotic cell engulfment. FEBS Lett 2008;582(15):2161-6
   PubMed Web of Science ®Google Scholar
• Smart N, Risebro CA, Melville AA, et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature 2007;445(7124):177-82
   PubMed Web of Science ®Google Scholar
• Conte E, Genovese T, Gili E, et al. Thymosin beta4 protects C57BL/6 mice from bleomycin-induced damage in the lung. Eur J Clin Invest 2013;43(3):309-15
   PubMed Web of Science ®Google Scholar
• Peng H, Xu J, Yang XP, et al. Thymosin-beta4 prevents cardiac rupture and improves cardiac function in mice with myocardial infarction. Am J Physiol Heart Circ Physiol 2014;307(5):H741-51
   PubMed Web of Science ®Google Scholar
• Sosne G, Christopherson PL, Barrett RP, et al. Thymosin-beta4 modulates corneal matrix metalloproteinase levels and polymorphonuclear cell infiltration after alkali injury. Invest Ophthalmol Vis Sci 2005;46(7):2388-95
   PubMed Web of Science ®Google Scholar
• Evans MA, Smart N, Dube KN, et al. Thymosin beta4-sulfoxide attenuates inflammatory cell infiltration and promotes cardiac wound healing. Nat Commun 2013;4:2081
   PubMed Web of Science ®Google Scholar
• Castoldi G, di Gioia CR, Bombardi C, et al. Renal antifibrotic effect of N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats. Am J Nephrol 2013;37(1):65-73
   PubMed Web of Science ®Google Scholar
• Shibuya K, Kanasaki K, Isono M, et al. N-acetyl-seryl-aspartyl-lysyl-proline prevents renal insufficiency and mesangial matrix expansion in diabetic db/db mice. Diabetes 2005;54(3):838-45
   PubMed Web of Science ®Google Scholar
• Zuo Y, Chun B, Potthoff SA, et al. Thymosin beta4 and its degradation product, Ac-SDKP are novel reparative factors in renal fibrosis. Kidney Int 2013;84(6):1166-75
   PubMed Web of Science ®Google Scholar
• Guinobert I, Viltard M, Piquemal D, et al. Identification of differentially expressed genes between fetal and adult mouse kidney: candidate gene in kidney development. Nephron Physiol 2006;102(3-4):81-91
   Web of Science ®Google Scholar
• Brunskill EW, Georgas K, Rumballe B, et al. Defining the molecular character of the developing and adult kidney podocyte. PLoS One 2011;6(9):e24640
   PubMedGoogle Scholar
• Nemolato S, Cabras T, Fanari MU, et al. Immunoreactivity of thymosin beta 4 in human foetal and adult genitourinary tract. Eur J Histochem 2010;54(4):e43
   PubMedGoogle Scholar
• Xu BJ, Shyr Y, Liang X, et al. Proteomic patterns and prediction of glomerulosclerosis and its mechanisms. J Am Soc Nephrol 2005;16(10):2967-75
   PubMed Web of Science ®Google Scholar
• Zhu J, Su LP, Zhou Y, et al. Thymosin beta4 Attenuates Early Diabetic Nephropathy in a Mouse Model of Type 2 Diabetes Mellitus. Am J Ther 2013. [ Epub ahead of print]
   Web of Science ®Google Scholar
• Cavasin MA, Liao TD, Yang XP, et al. Decreased endogenous levels of Ac-SDKP promote organ fibrosis. Hypertension 2007;50(1):130-6
   PubMed Web of Science ®Google Scholar
• Wang M, Liu R, Jia X, et al. N-acetyl-seryl-aspartyl-lysyl-proline attenuates renal inflammation and tubulointerstitial fibrosis in rats. Int J Mol Med 2010;26(6):795-801
   PubMed Web of Science ®Google Scholar
• Liao TD, Yang XP, D’Ambrosio M, et al. N-acetyl-seryl-aspartyl-lysyl-proline attenuates renal injury and dysfunction in hypertensive rats with reduced renal mass: council for high blood pressure research. Hypertension 2010;55(2):459-67
   PubMed Web of Science ®Google Scholar
• Rhaleb NE, Pokharel S, Sharma U, et al. Renal protective effects of N-acetyl-Ser-Asp-Lys-Pro in deoxycorticosterone acetate-salt hypertensive mice. J Hypertens 2011;29(2):330-8
   PubMed Web of Science ®Google Scholar
• Omata M, Taniguchi H, Koya D, et al. N-acetyl-seryl-aspartyl-lysyl-proline ameliorates the progression of renal dysfunction and fibrosis in WKY rats with established anti-glomerular basement membrane nephritis. J Am Soc Nephrol 2006;17(3):674-85
   PubMed Web of Science ®Google Scholar
• Long DA, Norman JT, Fine LG. Restoring the renal microvasculature to treat chronic kidney disease. Nat Rev Nephrol 2012;8(4):244-50
   PubMed Web of Science ®Google Scholar
• Azizi M, Ezan E, Reny JL, et al. Renal and metabolic clearance of N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) during angiotensin-converting enzyme inhibition in humans. Hypertension 1999;33(3):879-86
   PubMed Web of Science ®Google Scholar
• Le Meur Y, Lorgeot V, Comte L, et al. Plasma levels and metabolism of AcSDKP in patients with chronic renal failure: relationship with erythropoietin requirements. Am J Kidney Dis 2001;38(3):510-17
   PubMed Web of Science ®Google Scholar
• Rieger KJ, Saez-Servent N, Papet MP, et al. Involvement of human plasma angiotensin I converting enzyme in the degradation of the haemoregulatory peptide N-acetyl-seryl-aspartyl-lysyl-proline. Biochem J 1993;296(Pt 2):373-8
   PubMedGoogle Scholar